Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M83.4Revenue (TTM) $M33.9Net Margin (%)14.0Altman Z-Score1.0
Enterprise Value $M100EPS (TTM) $0.1Operating Margin %7.0Piotroski F-Score4
P/E(ttm)13.8Beneish M-Score2.5Pre-tax Margin (%)2.1Higher ROA y-yY
Price/Book1.710-y EBITDA Growth Rate %--Quick Ratio1.3Cash flow > EarningsN
Price/Sales2.45-y EBITDA Growth Rate %57.5Current Ratio2.1Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)6.3Higher Current Ratio y-yN
Dividend Yield %--PEG0.3ROE % (ttm)11.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M78.0ROIC % (ttm)6.3Gross Margin Increase y-yY

Gurus Latest Trades with NEPT

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

NEPT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NEPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Montgomery, Adrian TaylorDirector 2014-12-03Buy11,000$2.21-50.23view
Godin, AndréSenior Officer 2014-11-12Buy3,000$2.15-48.84view
Lemieux, PierreDirector or Senior Officer of Insider or Subsidiar 2014-11-12Buy5,000$2.19-49.77view
Godin, AndréSenior Officer 2014-11-11Buy8,000$2.12-48.11view
Ripplinger, JohnSenior Officer 2014-11-11Buy3,550$2.12-48.11view
Turcotte, MarioSenior Officer 2014-11-11Buy6,870$2.14-48.6view
Fitzgibbon, PierreDirector 2014-11-10Buy37,500$2.09-47.37view
Huart, BenoîtDirector 2014-11-10Buy7,000$2.03-45.81view
Lauzon, ClaudieSenior Officer 2014-11-10Buy2,400$2.08-47.12view
Le Bel, DominiqueSenior Officer 2014-11-10Buy10,000$2.01-45.27view

Press Releases about NEPT :

Quarterly/Annual Reports about NEPT:

    News about NEPT:

    Articles On GuruFocus.com
    What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

    More From Other Websites
    Neptune Tech posts 3Q profit Jan 12 2017
    Neptune Tech posts 3Q profit Jan 12 2017
    Acasti Pharma Reports Third Quarter 2017 Financial Results Jan 12 2017
    Neptune Announces Record Third Quarter Results Jan 12 2017
    Neptune to Hold Conference Call to Discuss Third Quarter Results for the Period Ended November 30,... Jan 04 2017
    Neptune to Hold Conference Call to Discuss Third Quarter Results for the Period Ended November 30,... Jan 04 2017
    Validity of Neptune’s Patent Upheld by Australian Patent Office / Third Challenge by Enzymotec... Nov 08 2016
    Neptune Announces Stock Ticker Symbol Change to NEPT on the TSX Nov 08 2016
    Validity of Neptune's Patent Upheld by Australian Patent Office Nov 07 2016
    Neptune Announces Stock Ticker Symbol Change to NEPT on the TSX Nov 04 2016
    Acasti Announces Stock Ticker Symbol Change to ACST on the TSXV Nov 03 2016
    Acasti Pharma Builds Intellectual Property Portfolio with Newly Issued U.S. Patent for CaPre Oct 26 2016
    Neptune Technologies & Bioresources, Inc. :NEPT-US: Earnings Analysis: Q2, 2017 By the Numbers :... Oct 18 2016
    Neptune Announces Q2 FY 2017 Results Oct 12 2016
    Neptune Announces Second Quarter Results Oct 12 2016
    Acasti Pharma Reports Second Quarter 2017 Financial Results Oct 11 2016
    Neptune and Ingenutra Sign an Exclusive Worldwide Agreement for MaxSimil® Oct 07 2016
    Here’s Why Aurinia Pharmaceuticals, Georgetown Bancorp, and Three Other Stocks Are on the Move... Oct 06 2016
    Neptune and Aker BioMarine Reach Important Patent Agreement, Recognizing the Patents' Strength and... Oct 04 2016
    Neptune and Aker BioMarine reach important patent agreement Oct 03 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)